title: Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
authors.affiliation: APHP, Department of Hemato-Oncology, Hopital Saint-Louis, Paris, France.|Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Cabannes-Hamy
authors.affiliation: CHU Clermont-Ferrand, Service D'hématologie Clinique Adulte Et De Thérapie Cellulaire, Clermont-Ferrand, 63003, France.|Clermont Université, Université D'auvergne, EA7283, CIC501, BP, , Clermont-Ferrand, 10448, 63000, France.
authors.forename: Richard
authors.initials: R
authors.lastname: Lemal
authors.affiliation: APHP, Department of Pharmacology, Hopital Saint-Louis, Paris, France.
authors.forename: Lauriane
authors.initials: L
authors.lastname: Goldwirt
authors.affiliation: Centre Hospitalier De Valenciennes, Service d'Hématologie-Immunologie-Cytogénétique, Valencia, France.|Centre De Biologie Et Pathologie, Laboratoire D'hématologie, INSERM UMR 1172, IRCL, CHRU De Lille, Lille, France.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Poulain
authors.affiliation: APHP, Department of Hemato-Oncology, Hopital Saint-Louis, Paris, France.|Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors.forename: Sandy
authors.initials: S
authors.lastname: Amorim
authors.affiliation: CHU Clermont-Ferrand, Pôle De Radiologie, Clermont-Ferrand, 63003, France.
authors.forename: Renan
authors.initials: R
authors.lastname: Pérignon
authors.affiliation: Hématologie Biologique, Centre De Ressources Biologiques D'auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, 63003, France.
authors.forename: Juliette
authors.initials: J
authors.lastname: Berger
authors.affiliation: APHP, Department of Hemato-Oncology, Hopital Saint-Louis, Paris, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
authors.affiliation: APHP, Department of Radiology, Hopital Saint-Louis, Paris, France.
authors.forename: Eric
authors.initials: E
authors.lastname: De Kerviler
authors.affiliation: CHU Clermont-Ferrand, Service D'hématologie Clinique Adulte Et De Thérapie Cellulaire, Clermont-Ferrand, 63003, France.|Clermont Université, Université D'auvergne, EA7283, CIC501, BP, , Clermont-Ferrand, 10448, 63000, France.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.affiliation: APHP, Department of Pharmacology, Hopital Saint-Louis, Paris, France.
authors.forename: Helene
authors.initials: H
authors.lastname: Sauvageon
authors.affiliation: EA7324, Paris Descartes Université, Sorbonne Paris Cité, Paris, France.
authors.forename: Kheira
authors.initials: K
authors.lastname: Beldjord
authors.affiliation: APHP, Department of Pharmacology, Hopital Saint-Louis, Paris, France.
authors.forename: Samia
authors.initials: S
authors.lastname: Mourah
authors.affiliation: CHU Clermont-Ferrand, Service D'hématologie Clinique Adulte Et De Thérapie Cellulaire, Clermont-Ferrand, 63003, France.|Clermont Université, Université D'auvergne, EA7283, CIC501, BP, , Clermont-Ferrand, 10448, 63000, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
authors.affiliation: APHP, Department of Hemato-Oncology, Hopital Saint-Louis, Paris, France.|Université Paris Diderot, Sorbonne Paris Cité, Paris, France.|EA7324, Paris Descartes Université, Sorbonne Paris Cité, Paris, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D002493:Central Nervous System Diseases / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D013577:Syndrome; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000097:blood / Q000134:cerebrospinal fluid / Q000150:complications* / Q000188:drug therapy
chemical_list: D007075:Immunoglobulin M; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000225:Adenine